 | | |
|
|
|
Wall Street darlings
Ranked by ratio of market value to revenue.
| 1 |
Oxigene |
<$0.1 |
$107.4 |
107,436.1 |
| 2 |
Interleukin Genetics Inc. |
<$0.1 |
$127.5 |
5,543.8 |
| 3 |
Point Therapeutics |
$0.2 |
$108.8 |
676 |
| 4 |
Panacos Pharmaceuticals |
$1.0 |
$341.1 |
325.1 |
| 5 |
Ariad Pharmaceuticals |
$1.2 |
$360.6 |
296.3 |
| 6 |
Pressure BioSciences |
$0.1 |
$11.6 |
109.8 |
| 7 |
Beacon Power Corp. |
$1.5 |
$108.5 |
73 |
| 8 |
NitroMed |
$6.0 |
$425.2 |
70.3 |
| 9 |
Ibis Technology Corp. |
$0.6 |
$37.6 |
62.4 |
| 10 |
Alnylam Pharmaceuticals |
$5.7 |
$355.8 |
62.2 |
NOTE: Company stock must have been traded on Dec. 30, 2005, with a price of $1 a share or higher, and a market value of $1 million or higher.
SOURCE: Standard & Poor's Compustat
|
|
|
|
|
